New pill for type 2 diabetes on the horizon

Embargoed until: Publicly released: 2025-03-04 03:00

International

CC:0

After finishing a trial on 113 patients, Chinese researchers believe they have another contender to help people with type 2 diabetes; in pill form. The medicine, called berberine ursodeoxycholate (HTD1801), caused patients to have significantly lower levels of hemoglobin A1c - a test for average blood sugar levels over an extended period - at the end of a 12-week trial. The study, which was funded by the drug company that created the medicine, notes that the treatment was safe and resulted in meaningful improvements to the patients' blood sugar levels as well as liver and heart health.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: Peking University People’s Hospital, Beijing, China

Funder: The study was sponsored by Shenzhen HighTide Biopharmaceutical Ltd. Prof Ji reported receiving consulting or lecture fees from Eli Lilly, Novo Nordisk, Merck, Bayer, Sanofi-Aventis, Roche, MSD, Metronics, AstraZeneca, Boehinger Ingelheim, Abbott, Fosun Pharma, Innovent Biologics, Gan & Lee Pharmaceuticals, Sinocare, Sibionics, and Shanghai Benemae Pharmaceutical Corp and being an independent director of Shanghai Benemae Pharmaceutical Corp outside the submitted work. Dr K. Liu reported having stock options in Shenzhen HighTide Biopharmaceutical Ltd outside the submitted work. Ms Yu reported having stock options in Shenzhen HighTide Biopharmaceutical Ltd outside the submitted work. Dr L. Liu reported having stock options in Shenzhen HighTide Biopharmaceutical Ltd outside the submitted work.

Media Contact/s

Contact details are only visible to registered journalists.